Edition:
India

Eidos Therapeutics Inc (EIDX.OQ)

EIDX.OQ on NASDAQ Stock Exchange Global Select Market

35.42USD
16 Oct 2019
Change (% chg)

-- (--)
Prev Close
$35.42
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
61,993
52-wk High
$49.50
52-wk Low
$9.03

Latest Key Developments (Source: Significant Developments)

Eidos Therapeutics Files For Mixed Shelf Of Upto $300 Mln
Saturday, 3 Aug 2019 

Aug 2 (Reuters) - Eidos Therapeutics Inc ::EIDOS THERAPEUTICS INC FILES FOR MIXED SHELF OF UPTO $300 MILLION - SEC FILING.  Full Article

Eidos Therapeutics Reports Q2 Loss Per Share Of $0.39
Friday, 2 Aug 2019 

Aug 1 (Reuters) - Eidos Therapeutics Inc ::EIDOS THERAPEUTICS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.39.Q2 EARNINGS PER SHARE ESTIMATE $-0.39 -- REFINITIV IBES DATA.CASH AND CASH EQUIVALENTS TOTALED $131.4 MILLION AT JUNE 30, 2019 COMPARED WITH $157.1 MILLION AT DECEMBER 31, 2018..  Full Article

Eidos Therapeutics Reports Q4 Loss Per Share Of $0.27
Monday, 15 Apr 2019 

April 15 (Reuters) - Eidos Therapeutics Inc ::EIDOS THERAPEUTICS REPORTS FOURTH QUARTER AND YEAR-END 2018 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.27.Q4 EARNINGS PER SHARE ESTIMATE $-0.25 -- REFINITIV IBES DATA.  Full Article

Eidos Therapeutics Says PWC's Audit Report On Financial Statements As Of & For Years Ended Dec 31, 2017, 2016 Should Not Be Relied Upon
Thursday, 21 Feb 2019 

Feb 21 (Reuters) - Eidos Therapeutics Inc ::EIDOS THERAPEUTICS - PWC ADVISED CO THAT PWC'S AUDIT REPORT ON FINANCIAL STATEMENTS AS OF AND FOR YEARS ENDED DEC 31, 2017, 2016 SHOULD NOT BE RELIED UPON.  Full Article

Eidos Therapeutics Receives Positive Opinion For Orphan Designation From The European Medicines Agency For AG10
Friday, 26 Oct 2018 

Oct 26 (Reuters) - Eidos Therapeutics Inc ::EIDOS THERAPEUTICS RECEIVES POSITIVE OPINION FOR ORPHAN DESIGNATION FROM THE EUROPEAN MEDICINES AGENCY FOR AG10, A POTENT ORAL STABILIZER FOR THE TREATMENT OF TRANSTHYRETIN AMYLOIDOSIS.EIDOS THERAPEUTICS INC - EUROPEAN MEDICINES AGENCY ALSO GRANTED A PRODUCT-SPECIFIC PEDIATRIC INVESTIGATIONAL PLAN WAIVER TO EIDOS FOR AG10.  Full Article

Eidos' Transthyretin Amyloidosis Treatment Gets Orphan Drug Status
Thursday, 4 Oct 2018 

Oct 3 (Reuters) - Eidos Therapeutics Inc ::FDA GRANTS ORPHAN DRUG DESIGNATION TO EIDOS THERAPEUTICS’ PRODUCT CANDIDATE, AG10, FOR TREATMENT OF TRANSTHYRETIN AMYLOIDOSIS.PLANS TO INITIATE PHASE 3 STUDIES IN FIRST HALF OF 2019.INVESTIGATING AG10 FOR TREATMENT OF ATTR CARDIOMYOPATHY (ATTR-CM) AND ATTR POLYNEUROPATHY (ATTR-PN).  Full Article

RA Capital Management Reports 5.9 Pct Stake In Eidos Therapeutics Inc As Of June 22
Tuesday, 3 Jul 2018 

July 2 (Reuters) - Eidos Therapeutics Inc ::RA CAPITAL MANAGEMENT REPORTS 5.9 PERCENT STAKE IN EIDOS THERAPEUTICS INC AS OF JUNE 22 - SEC FILING.RA CAPITAL MANAGEMENT SAYS ACQUIRED EIDOS THERAPEUTICS STOCK FOR "INVESTMENT PURPOSES".  Full Article

Eidos Therapeutics Shares Debut At $20, About 17 Pct Above IPO Price
Wednesday, 20 Jun 2018 

June 20 (Reuters) - :EIDOS THERAPEUTICS SHARES DEBUT AT $ 20 ON NASDAQ VERSUS IPO PRICE OF $17/SHARE.  Full Article

Eidos Therapeutics Announces Pricing Of Initial Public Offering
Wednesday, 20 Jun 2018 

June 19 (Reuters) - Eidos Therapeutics Inc ::EIDOS THERAPEUTICS ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING.SAYS INITIAL PUBLIC OFFERING OF 6.25 MILLION COMMON SHARES PRICED AT $17 PER SHARE.  Full Article